Chinese Biotech Investors Have Caught a Chill

摘要

Four years ago, President Xi Jinping's government rolled out the Made in China 2025 strategy to dominate the global economy with its homegrown technology. Chinese government-backed venture capital firms that still wanted to buy U.S. assets identified health care as a sector they could invest in without running afoul of regulators at home.